Andrea Pfeifer, AC Immune CEO (AC Immune)
August 31, 2021 11:05 AM EDTUpdated 01:59 PM
R&D

Cau­tious­ly op­ti­mistic, AC Im­mune de­liv­ers a mixed set of Alzheimer's da­ta — but in­vestors love it

Max Gelman

Senior Editor

Swiss biotech AC Im­mune is trad­ing sharply high­er Tues­day morn­ing fol­low­ing the re­lease of mixed topline Alzheimer’s da­ta.

First, the good news: In a dou­ble …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times